TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00386412
Recruitment Status : Completed
First Posted : October 11, 2006
Last Update Posted : September 18, 2009
Information provided by:
PETHEMA Foundation

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2009
  Actual Study Completion Date : September 2009
Einsele H, Reusser P, Hertenstein B, Bornhäuser M, Kröger N, Kahls P, et al. Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD. Blood 2004;104(11):abstract 2239.